We were at the ADA and AACE and have over 45 video interviews with some great information. Would you prefer to watch a video interview in its entirety, or an interview broken up into Q&A segments? Follow the link and let us know your opinion!

New study indicates canagliflozin superior to glimepiride in lowering A1C.

I just did a CE program for consultant pharmacists in Lake Mary, Florida. We were discussing the reasons why we may not try to work to perfection with our older patients. One of my colleagues brought up the 5-star ratings and how one of the measurements had to do with …

Diabetes screening should be protocol test in all health centers, health fairs to prevent undiagnosed diabetes and avoid later complications.

New data presented at AACE shows hypoglycemic events are less likely in patients with diabetes treated with an electronic glycemic management system.

Novo Nordisk announced positive results on its pipeline GLP-1 candidate, semaglutide, from the phase IIIa trial, SUSTAIN 4 and 5.

In this Exclusive Interview, Dr. Joseph Aloi joins Diabetes in Control publisher Steve Freed for a discussion at the AACE 2016 convention in in Orlando, Florida, to discuss how software can help treat diabetic ketoacidosis.

This interview is also available as a video: click here to view. Dr. Joseph Aloi, Wake Forest Baptist Medical Center, Winston-Salem, NC. Steve: This is Steve Freed with Diabetes in Control and we’re here at AACE 2016 and we have with us a special guest who’s been working on some unique …

Guest article by David Kliff, Diabetic Investor: Panel further assessing date that SGLT-2 drug shows actual benefit for heart.

More stringent hyperglycemia management (target A1C 6-6.5%) in type 2 diabetes might be supported by which one of the following factors: A. Long-standing disease duration B. Moderate-severe vascular complications C. Shorter life expectancy D. Absent-few comorbidities Are you right? Follow the link to find out!